GlassScriptPhysician profile
Lisa Ortenzi
NPI 1538153101
$2,851.12
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $796 · 2020: $724 · 2021: $1,269 · 2022: $61.74.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $654.79 | 2019-2022 | |
| Avion Pharmaceuticals | $233.05 | 2019-2021 | |
| Novo Nordisk INC | $162.62 | 2020-2021 | |
| Pfizer INC. | $149.31 | 2019-2022 | |
| Therapeuticsmd, INC. | $149.20 | 2019-2021 | |
| Merz North America, INC. | $143.91 | 2019-2021 | |
| Amgen INC. | $141.40 | 2020-2021 | |
| Ascend Therapeutics US, LLC | $137.94 | 2019-2021 | |
| Lupin INC. | $123.93 | 2019-2021 | |
| Mayne Pharma Commercial LLC | $120.05 | 2021 | |
| Exeltis, USA INC. | $113.54 | 2019-2021 | |
| Astellas Pharma US INC | $105.16 | 2019-2021 | |
| Duchesnay USA Incorporated | $85.44 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $84.10 | 2019-2020 | |
| Allergan, INC. | $82.14 | 2019-2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Millicent US INC | $64.81 | 2020 | |
| Evofem Biosciences, INC. | $60.46 | 2021 | |
| Myovant Sciences INC. | $60.14 | 2021-2022 | |
| Currax Pharmaceuticals LLC | $41.64 | 2020-2021 | |
| Nalpropion Pharmaceuticals LLC | $31.27 | 2019 | |
| Zyla Life Sciences, INC. | $28.42 | 2020 | |
| Vertical Pharmaceuticals, LLC | $19.87 | 2019 | |
| Agile Therapeutics, INC. | $17.26 | 2021 | |
| Mylan Pharmaceuticals INC. | $15.02 | 2019 | |
| Assertio Therapeutics, INC. | $13.01 | 2020 | |
| Virtus Pharmaceuticals LLC | $12.64 | 2021 |
3 companies reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Ortenzi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.